menu search

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Alpine immune sciences announces participation in march investor conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

March 1, 2022, 8:05 am

Alpine immune sciences announces participation in march investor conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

March 1, 2022, 8:05 am

Alpine immune sciences announces participation in march investor conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

March 1, 2022, 8:05 am

Argenx to present at the 42nd annual cowen health care conference

February 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 28, 2022, 1:00 am

Argenx to present at the 42nd annual cowen health care conference

February 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 28, 2022, 1:00 am

Argenx to present at the 42nd annual cowen health care conference

February 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 28, 2022, 1:00 am

Argenx to report full year 2021 financial results and fourth quarter business update on march 3, 2022

February 24, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 24, 2022, 1:00 am

Argenx to report full year 2021 financial results and fourth quarter business update on march 3, 2022

February 24, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 24, 2022, 1:00 am

Argenx to report full year 2021 financial results and fourth quarter business update on march 3, 2022

February 24, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 24, 2022, 1:00 am

Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldo

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

February 18, 2022, 6:30 am

Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldo

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

February 18, 2022, 6:30 am

Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldo

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

February 18, 2022, 6:30 am

Immunic, inc. to announce financial results for the year ended december 31, 2021 and provide corporate update

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

February 17, 2022, 6:30 am

Immunic, inc. to announce financial results for the year ended december 31, 2021 and provide corporate update

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

February 17, 2022, 6:30 am

Immunic, inc. to announce financial results for the year ended december 31, 2021 and provide corporate update

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

February 17, 2022, 6:30 am

Argenx to present at the 11th annual svb leerink global healthcare conference

February 10, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 10, 2022, 1:00 am

Argenx to present at the 11th annual svb leerink global healthcare conference

February 10, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 10, 2022, 1:00 am

Argenx to present at the 11th annual svb leerink global healthcare conference

February 10, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

February 10, 2022, 1:00 am


Search within

Pages Search Results: